Protein scaffolds in human clinics

Biotechnol Adv. 2022 Dec:61:108032. doi: 10.1016/j.biotechadv.2022.108032. Epub 2022 Sep 9.

Abstract

Fundamental clinical areas such as drug delivery and regenerative medicine require biocompatible materials as mechanically stable scaffolds or as nanoscale drug carriers. Among the wide set of emerging biomaterials, polypeptides offer enticing properties over alternative polymers, including full biocompatibility, biodegradability, precise interactivity, structural stability and conformational and functional versatility, all of them tunable by conventional protein engineering. However, proteins from non-human sources elicit immunotoxicities that might bottleneck further development and narrow their clinical applicability. In this context, selecting human proteins or developing humanized protein versions as building blocks is a strict demand to design non-immunogenic protein materials. We review here the expanding catalogue of human or humanized proteins tailored to execute different levels of scaffolding functions and how they can be engineered as self-assembling materials in form of oligomers, polymers or complex networks. In particular, we emphasize those that are under clinical development, revising their fields of applicability and how they have been adapted to offer, apart from mere mechanical support, highly refined functions and precise molecular interactions.

Keywords: Protein materials; drug delivery; human protein; humanization; nanomedicine; regenerative medicine, self-assembling.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Biocompatible Materials* / chemistry
  • Drug Delivery Systems
  • Humans
  • Polymers / chemistry
  • Proteins*
  • Regenerative Medicine
  • Tissue Engineering

Substances

  • Biocompatible Materials
  • Proteins
  • Polymers